STOCK TITAN
  1. Home
  2. Sec-filings
  3. PROK
  4. [Form 4] PROKIDNEY CORP. Insider Trading Activity

ProKidney (NASDAQ: PROK) grants 135,000 stock options to director

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

PROKIDNEY CORP. director Uma Sinha received a grant of options to buy 135,000 shares of Class A Common Stock at an exercise price of $1.81 per share. These director options were granted under the company’s non-employee director compensation policy and will vest in full on the earlier of one year from grant or the next annual general shareholder meeting.

Positive

  • None.

Negative

  • None.
Insider Sinha Uma
Role null
Type Security Shares Price Value
Grant/Award Director stock option (right to buy) 135,000 $0.00 --
Holdings After Transaction: Director stock option (right to buy) — 135,000 shares (Direct, null)
Footnotes (1)
  1. These options were granted under the Issuer's non-employee director compensation policy. The options will vest in full on the sooner of the one-year anniversary of the date of grant or the date of Company's next annual general shareholder meeting.
Options granted 135,000 options Director stock option grant on May 28, 2026
Exercise price $1.81 per share Conversion/exercise price for director options
Expiration date May 28, 2036 Option term end for 135,000-share grant
Underlying shares 135,000 shares Class A Common Stock underlying the options
Post-grant derivative holdings 135,000 options Total options held following this transaction
Director stock option financial
"Director stock option (right to buy)"
non-employee director compensation policy financial
"These options were granted under the Issuer's non-employee director compensation policy."
vest in full financial
"The options will vest in full on the sooner of the one-year anniversary of the date of grant"
annual general shareholder meeting financial
"or the date of Company's next annual general shareholder meeting."
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Sinha Uma
(Last)(First)(Middle)
C/O PROKIDNEY CORP
2000 FRONTIS PLAZA BLVD, SUITE 250
(Street)
WINSTON SALEM NORTH CAROLINA 27103
(City)(State)(Zip)
UNITED STATES
(Country)		2. Issuer Name and Ticker or Trading Symbol
PROKIDNEY CORP. [ PROK ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
Officer (give title below)Other (specify below)
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
05/28/2026		6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Director stock option (right to buy)$1.8105/28/2026A135,000(1) (2)05/28/2036Class A Common Stock135,000$0135,000D
Explanation of Responses:
1. These options were granted under the Issuer's non-employee director compensation policy.
2. The options will vest in full on the sooner of the one-year anniversary of the date of grant or the date of Company's next annual general shareholder meeting.
/s/ Todd Girolamo, attorney in fact05/29/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What did ProKidney (PROK) director Uma Sinha report in this Form 4?

Director Uma Sinha reported receiving a grant of options for 135,000 shares of ProKidney Class A Common Stock. These options are a compensation award under the non-employee director policy, not an open-market purchase or sale of existing shares.

What is the exercise price of Uma Sinha’s ProKidney stock options?

The director stock options have an exercise price of $1.81 per share. This means Sinha can buy ProKidney Class A Common Stock at $1.81 per share once the options are vested and exercised, subject to the option terms and expiration date.

How many ProKidney shares are covered by the new director stock option grant?

The grant covers options for 135,000 underlying shares of ProKidney Class A Common Stock. Following this grant, the Form 4 shows total derivative holdings of 135,000 options for Sinha, all from this award, held in direct ownership form.

When do Uma Sinha’s ProKidney director stock options vest?

The options vest in full on the earlier of two dates: the one-year anniversary of the grant date or ProKidney’s next annual general shareholder meeting. This single cliff-vesting schedule is set out in the footnotes to the Form 4 filing.

When do the reported ProKidney stock options held by Uma Sinha expire?

The stock options are scheduled to expire on May 28, 2036, according to the Form 4 data. After this expiration date, any unexercised options from the 135,000-share grant would lapse and could no longer be exercised for Class A Common Stock.

Is the ProKidney Form 4 for Uma Sinha a purchase or a compensation grant?

The Form 4 reflects a compensation grant, not an open-market purchase. It shows a code A transaction, described as a grant or award acquisition, issued under ProKidney’s non-employee director compensation policy, with zero cash price paid at the time of grant.